The global hemoglobinopathies market size was US$ 4.2 billion in 2021. The global hemoglobinopathies market size is estimated to reach US$ 6.6 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.2% during the forecast period from 2022 to 2030.
Hemoglobinopathies are a group of diseases inherited from parents to offspring. Hemoglobinopathies are caused by mutations in the gene for the hemoglobin molecule. The two main types of hemoglobinopathies are hemoglobin (Hb) variants caused by hemoglobin gene mutations and thalassemia caused by insufficient hemoglobin production. Different hemoglobinopathies, such as thalassemia, sickle cell disease, hemoglobin variants, and beta thalassemia lead to different health problems. In addition, health problems associated with the disease are heart problems, blurred vision, slow growth, spleen enlargement, gallstones, and stroke.

Factors Affecting Marketing Growth

The development and research for the treatment are increased, which leads to boosting the growth of the global market.
An increase in disease count, new methods adopted for screening, and novel research and development activities are expected to drive the growth of the global market.
The various pharmaceutical leaders of the industry are involved in novel treatment development, which is expected to drive the growth of the global market.
The high-cost treatment and lack of awareness hinder the growth of the global market.

Impact on COVID-19 Analysis

The COVID-19 outbreak resulted in a substantial decline in demand for the global hemoglobinopathies market across several sectors, particularly the health and pharmaceutical sectors. The main cause of the interruptions experienced by patients getting treatment for hemoglobinopathies in hospitals was the risk of infection. Thus, COVID-19 had a negative impact on the growth of the global market.

Regional Analysis

North America was the highest revenue contributor, due to an increase in the number of hemoglobinopathies, an increase in patients seeking hemoglobinopathy treatment, and increased R&D Activities. Furthermore, the availability of new pharmacological therapies and diagnostic methods for hemoglobinopathies treatment drives the growth of the global market in the region.

Leading Competitors
The prominent players in the global hemoglobinopathies market are:
Gamida-Cell Ltd
Sanofi
Cancer Therapeutics CRC Pty Ltd
Sangamo Therapeutics
Prolong Pharmaceuticals
Global Blood Therapeutics
Emmaus Life Sciences
Bristol Myers Squibb
Biogen IDC
Alnylam Pharmaceuticals
Abbott Laboratories
Others
Segmentation Analysis
The global hemoglobinopathies market segmentation focuses on Type, Therapy, Distribution Channel, and Region.
Segmentation on the basis of Type
Sickle Cell Disease
Thalassemia
Others

Segmentation on the basis of Therapy
Hydroxyurea
Monoclonal Antibody Medication
ACE inhibitors
Others

Segmentation on the basis of Distribution Channel
Drug Stores and Retail Pharmacy
Hospital Pharmacy
Online Providers
Segmentation on the basis of Region
North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
UAE
Saudi Arabia
South Africa
Rest of MEA
South America
Brazil
Argentina
Rest of South America